


Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



SINO BIOPHARMACEUTICAL LIMITED
中國生物製藥有限公司

(Incorporated in the Cayman Islands with limited liability)

Website: www.sinobiopharm.com

(Stock code: 1177)

VOLUNTARY ANNOUNCEMENT
PRIORITISED EVALUATION GRANTED FOR
KRAS G12C INHIBITOR “GARSORASIB TABLET (D-1553)”

The board of directors (the “**Board**”) of Sino Biopharmaceutical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) announces that KRAS G12C Inhibitor “Garsorasib Tablet (D-1553)”, which is codeveloped by the Group, has been included in the List of Products for Prioritized Evaluation (優先審評品種名單) by the Center for Drug Evaluation (“**CDE**”) of the National Medical Products Administration of China.

D-1553 is the first domestic independently developed KRAS G12C inhibitor to enter clinical trials stage. In June 2022, D-1553 was granted Breakthrough Therapy designation by the CDE, being the first domestic KRAS G12C inhibitor which was granted Breakthrough Therapy designation by the CDE. In December 2023, the new drug application for D-1553 was formally accepted by the CDE for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC) with disease progression following or intolerant to prior first-line systemic therapy and with confirmed KRAS G12C mutation.

At this stage, the Group is currently cooperating with InventisBio Co., Ltd. to promote clinical trials of D-1553 for the first-line treatment of NSCLC and other solid tumours, and it is anticipated that the indications for D-1553 will be further expanded in the coming years and hopefully another heavyweight oncology product that is comparable to Anlotinib will be developed.

At present, there is no KRAS G12C targeted drug available in the PRC market. The grant of prioritised evaluation for D-1553 is expected to accelerate the evaluation for market launch of D-1553, to address the unmet clinical needs as soon as possible for the benefit of the domestic patients, and on the other hand, it marks the successful layout of the Group’s another important and advantageous product in the field of NSCLC after Anlotinib. In the future, the Group will continue to focus on NSCLC and bring new treatment options to patients.

By order of the Board
Sino Biopharmaceutical Limited
Tse, Theresa Y Y
Chairwoman

Hong Kong, 23 January 2024

As at the date of this announcement, the Board of the Company comprises seven executive directors, namely Ms. Tse, Theresa Y Y, Mr. Tse Ping, Ms. Cheng Cheung Ling, Mr. Tse, Eric S Y, Mr. Tse Hsin, Mr. Tian Zhoushan and Ms. Li Mingqin and five independent non-executive directors, namely Mr. Lu Zhengfei, Mr. Li Dakui, Ms. Lu Hong, Mr. Zhang Lu Fu and Dr. Li Kwok Tung Donald.